Inclusion Criteria:

          -  M1A or B NSCLC with any number of prior therapies or any stage Small cell Lung Cancer
             (SCLC) with any number of prior therapies

          -  Planned systemic therapy (i.e. intent to treat)

          -  Provision of written informed consent for biospecimen storage, broad genetic and
             proteomic analysis of tumor and normal tissues, without restrictions, AND correlation
             with outcome data

          -  Aged 18 years and over.

          -  Measurable or evaluable disease.

          -  ECOG performance status of 0-2 with expected survival of at least 3 months.

          -  Tumor specimens:

          -  Tumor specimens:

          -  4.7.1 First Priority: availability of a minimum of a 1 X 10 mm core fresh frozen
             tumor, or ≥3 mm diameter spherical pellet from a pleural effusion (≥50% tumor cells),
             or ≥3 mm diameter spherical pellet from a fine needle aspirate (≥50% tumor cells) from
             clinically indicated interventional procedures, with no systemic anti-cancer therapy
             or radiation to all sites of evaluable disease between collection of the biopsy and
             entry into the study (e.g. if a brain metastasis was radiated but the lung tumor was
             not, then the latter could still be biopsied and the subject enrolled after radiation
             therapy of the brain metastasis (and vice versa)).

        or

          -  Second Priority: availability of paraffin-embedded tumor (via biopsies or pleural
             effusions) at least 5 X 5 mm (3 X 3 mm for pleural effusions) cross-sectional tumor
             area, with no systemic anti-cancer therapy or radiation to all sites of evaluable
             disease between collection of the biopsy and entry into the study; the collection of
             the paraffin-embedded tissues may have taken place up to 12 months prior to enrollment
             in CASTLE.

          -  Willingness to undergo all study collection procedures and sample analyses including
             prerequisite baseline molecular testing via ResponseDX: Lung (Response Genetics Inc.)
             and VeriStrat (Biodesix) - see 6.3 below for details.

          -  Exclusion criteria

          -  Other co-existing malignancies except for basal cell carcinoma or cervical cancer in
             situ.

          -  Compromise of patient diagnosis or staging if tissue is harvested for research